Palvella Therapeutics adds Matthew Pauls to board of directors

Palvella Therapeutics, Inc. announced that on June 29, 2026, its board of directors expanded from seven to eight members and appointed Matthew Pauls as a Class I director. The Board increased its size from seven to eight members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Pauls to serve as a Class I director, with an initial term expiring at the Company's 2027 Annual Meeting of Stockholders.¹

Pauls, 56, currently leads Savara, Inc. where he has served as Chief Executive Officer of the public clinical-stage biopharmaceutical company focused on rare respiratory diseases since December 2020.¹ Earlier in his career, he served as President and Chief Executive Officer of Strongbridge Biopharma plc, a public biopharmaceutical company focused on rare respiratory diseases that was acquired by Xeris Pharmaceuticals, Inc., where he led the company through its Nasdaq initial public offering, oversaw commercialization of KEVEYIS and Macrilen, and advanced RECORLEV through pivotal Phase 3 development for Cushing's syndrome.¹

Pauls also previously served on the board of Soleno Therapeutics from 2023 to 2026, including as Lead Independent Director from 2024 until its $2.9 billion acquisition by Neurocrine Biosciences in 2026.¹ During his tenure, Soleno secured FDA approval and successfully launched VYKAT XR, the first and only FDA-approved treatment for hyperphagia in patients with Prader-Willi syndrome, a serious, rare genetic disease.¹

As part of the appointment, Pauls was granted an option to purchase 6,000 shares of the company's common stock, vesting in equal monthly installments over thirty-six months, subject to continued service.¹ The Board determined that Pauls is independent under applicable Nasdaq listing rules.¹